These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 25180766)

  • 1. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.
    Pollock KG; Kavanagh K; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Cruickshank M; Palmer TJ; Nicoll S; Donaghy M
    Br J Cancer; 2014 Oct; 111(9):1824-30. PubMed ID: 25180766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.
    Palmer T; Wallace L; Pollock KG; Cuschieri K; Robertson C; Kavanagh K; Cruickshank M
    BMJ; 2019 Apr; 365():l1161. PubMed ID: 30944092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
    Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
    J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
    Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Cotton S; Nicoll S; Robertson C
    Br J Cancer; 2016 Mar; 114(5):582-9. PubMed ID: 26931370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
    Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
    J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.
    Kavanagh K; Pollock KG; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Donaghy M
    Br J Cancer; 2014 May; 110(11):2804-11. PubMed ID: 24736582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
    Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.
    Cruickshank ME; Pan J; Cotton SC; Kavanagh K; Robertson C; Cuschieri K; Cubie H; Palmer T; Pollock KG
    BJOG; 2017 Aug; 124(9):1386-1393. PubMed ID: 28102928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
    Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
    Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
    J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
    Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
    Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
    Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
    Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Kann H; Hortlund M; Eklund C; Dillner J; Faust H
    Int J Cancer; 2020 May; 146(9):2539-2546. PubMed ID: 31868230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cobas 4800 HPV detection in the cervical, vaginal and urine samples of women with high-grade CIN before and after treatment.
    Stanczuk GA; Currie H; Baxter G; Foster A; Gibson L; Graham C; Cuschieri K
    J Clin Pathol; 2015 Jul; 68(7):567-70. PubMed ID: 25878328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
    Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.